ChemBriefKura Oncology launches diabetes-focused Caspian Therapeutics
Sep 9, 2026
Kura Oncology launched Caspian Therapeutics with $50 million to develop menin inhibitors for diabetes and cardiometabolic diseases. Backed by Eli Lilly and the T1D Fund, Kura retains a 50% stake in the new venture.